Cargando…
吉西他滨调整方案治疗晚期非小细胞肺癌的Ⅱ期临床试验
BACKGROUND AND OBJECTIVE: Gemcitabine-platinum-combined with chemotherapy is the most common treatment for advanced non-small cell lung cancer (NSCLC). Gemcitabine is administered once a week in a general three-week schedule. In the present study, gemcitabine is administered on d1 and d5 to improve...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999965/ https://www.ncbi.nlm.nih.gov/pubmed/22237116 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.01.01 |
Ejemplares similares
-
吉西他滨联合长春瑞滨方案一线治疗中国晚期非小细胞肺癌患者的多中心回顾性研究
Publicado: (2012) -
吉西他滨联合长春瑞滨方案治疗复治中国晚期非小细胞肺癌患者的多中心回顾性研究
Publicado: (2012) -
吉西他滨联合铂类两药方案与单药方案对非小细胞肺癌治疗比较的meta分析
Publicado: (2010) -
吉西他滨顺铂联合索拉非尼或安慰剂一线治疗晚期非小细胞肺癌的随机对照研究
Publicado: (2011) -
吉西他滨联合奥沙利铂或顺铂一线治疗老年晚期非小细胞肺癌的随机研究
Publicado: (2011)